Peter A. Calabresi

Research interests

Publications

• Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria

  The Lancet Neurology · 2025 · https://doi.org/10.1016/s1474-4422(25)00270-4

• Locus for severity implicates CNS resilience in progression of multiple sclerosis

  Nature · 2023 · https://doi.org/10.1038/s41586-023-06250-x

• Diagnosis and classification of optic neuritis

  The Lancet Neurology · 2022 · https://doi.org/10.1016/s1474-4422(22)00200-9

• Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30137-1

• Multiple Sclerosis

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmra1401483

• Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity

  Science · 2018 · https://doi.org/10.1126/science.aan4665

• Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis

  The Lancet Neurology · 2017 · https://doi.org/10.1016/s1474-4422(17)30278-8

• Cell-based therapeutic strategies for multiple sclerosis

  Brain · 2017 · https://doi.org/10.1093/brain/awx154

• Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis

  The Lancet Neurology · 2017 · https://doi.org/10.1016/s1474-4422(17)30278-8

• The APOSTEL recommendations for reporting quantitative optical coherence tomography studies

  Neurology · 2016 · https://doi.org/10.1212/wnl.0000000000002774

• Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

  The Lancet Neurology · 2016 · https://doi.org/10.1016/s1474-4422(16)00068-5

• Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

  The Lancet Neurology · 2014 · https://doi.org/10.1016/s1474-4422(14)70068-7

• Defining the clinical course of multiple sclerosis

  Neurology · 2014 · https://doi.org/10.1212/wnl.0000000000000560

• Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria

  Multiple Sclerosis Journal · 2014 · https://doi.org/10.1177/1352458514538110

• Ganglion Cell Loss in Relation to Visual Disability in Multiple Sclerosis

  Ophthalmology · 2012 · https://doi.org/10.1016/j.ophtha.2011.11.032

• Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

  The Lancet · 2011 · https://doi.org/10.1016/s0140-6736(11)61649-8

• A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa0909494

• Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial

  Annals of Neurology · 2008 · https://doi.org/10.1002/ana.21363

• The incidence and significance of anti-natalizumab antibodies

  Neurology · 2007 · https://doi.org/10.1212/01.wnl.0000277457.17420.b5

• Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

  Nature Medicine · 2000 · https://doi.org/10.1038/80525

Current projects

No projects listed.